Premium
Synergistic interaction between meloxicam and aminoguanidine in formalin‐induced nociception in mice
Author(s) -
Dudhgaonkar Shailesh P.,
Tandan Surendra K.,
Kumar Dinesh,
Arunadevi R.,
Prakash V. Ravi
Publication year - 2008
Publication title -
european journal of pain
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.305
H-Index - 109
eISSN - 1532-2149
pISSN - 1090-3801
DOI - 10.1016/j.ejpain.2007.06.006
Subject(s) - meloxicam , nociception , licking , pharmacology , chemistry , medicine , receptor , biochemistry
Objectives: The objective of this study was to examine the nature of interaction between cyclooxygenase‐2 inhibitor meloxicam and inducible nitric oxide synthase inhibitor aminoguanidine in formalin‐induced nociception in mice and the possible therapeutic advantage. Methods: Antinociceptive effect of meloxicam (1, 3, 10 and 30mg/kg, oral) and aminoguanidine (10, 30, 100 and 300mg/kg, oral) and their combinations was examined in formalin‐induced paw licking model in mice. Analysis of variance and isobolographic method were employed to identify the nature of antinociceptive interaction. Results: Higher doses of meloxicam (10 and 30mg/kg) and aminoguanidine (100 and 300mg/kg) produced significant reduction in paw licking time (antinociceptive) in late phase of formalin‐induced nociception. Combination of sub‐threshold dose of meloxicam (3mg/kg) with increasing doses of aminoguanidine (10, 30, 100 and 300mg/kg) resulted in synergistic antinociceptive effect. Similarly, co‐administration of sub‐threshold dose of aminoguanidine (30mg/kg) with increasing doses of meloxicam (1, 3, 10 and 30mg/kg) produced significant reduction in formalin‐induced paw licking behaviour. The experimental ED 50 for combination with their confidence limits are below the confidence interval of theoretical line of additive interaction, suggesting synergistic nature of interaction between meloxicam and aminoguanidine in isobolographic analysis. Conclusion: Co‐administration of meloxicam and aminoguanidine showed synergistic antinociceptive effect which might possibly reduce gastrointestinal toxicity associated with the use of meloxicam.